Lady in a white labcoat in a modern lab

CREDIT: 4BaseBio

4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies

Expanding capabilities in delivering scalable, high-quality synthetic DNA solutions to the global market
| 2 min read

Cambridge, UK, Tuesday 01 July 2025 – 4basebio PLC (AIM: 4BB) (“4basebio”), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.

Since completing its £40 million investment in November 2024, 4basebio has achieved several major milestones in its mission to deliver scalable, high-quality synthetic DNA solutions to the global market. Notably, in April this year, the Company received MHRA GMP certification for the manufacture and supply of synthetic DNA for clinical use1.

The updated brand identity introduces a refined visual system, including a modernised logo, refreshed colour palette, and a suite of new imagery. The Company’s redesigned website provides a more intuitive access point for partners and customers, providing detailed information and support for 4basebio’s expanding capabilities across synthetic DNA, mRNA, gene editing, and plasmid-free manufacturing. With a newly curated content hub, users can also access a range of specialist resources, including data, whitepapers, articles, case studies and more.

This brand refresh marks an exciting milestone for 4basebio,” said Heikki Lanckriet, CEO of 4basebio. “As we continue to scale our operations and deepen our work with partners across RNA, cell and gene therapy, and vaccine development, we wanted our identity to reflect the sophistication and innovation that define our approach. Our new website and branding communicate not just who we are, but where we’re going.

The rebrand aligns with 4basebio’s broader commercial strategy, which includes an increased presence at industry events, expanded customer engagement efforts, and a continued focus on delivering high-quality synthetic DNA starting materials for next-generation genetic medicines.

To learn more about 4basebio’s technology platforms, manufacturing services, GMP certification and recent partnerships, visit the new website: www.4basebio.com.

  1. Press Release (2nd April 2025): 4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNA
Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue